Imaging in drug development.
Imaging has played an important part in the diagnosis of disease and development of the understanding of the underlying disease mechanisms and is now poised to make an impact in the development of new pharmaceuticals. This chapter discusses the underlying technologies that make the field ready for this challenge. In particular, the potentials of magnetic resonance imaging and functional magnetic resonance imaging are outlined, including the new methods developed to provide additional information from the scans carried out. The field of nuclear medicine has seen a rapid increase in interest as advances in radiochemistry have enabled a wide range of new radiotracers to be synthesised.
GE Healthcare, The Grove Centre, Amersham, Buckinghamshire, United Kingdom.
James
J
Nairne
GE Healthcare, The Grove Centre, Amersham, Buckinghamshire, United Kingdom.
Peter B
PB
Iveson
GE Healthcare AS, Nydalen, Oslo, Norway.
Andreas
A
Meijer
D055808:Drug Discovery; D008279:Magnetic Resonance Imaging / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D057170:Translational Research, Biomedical
Clinical trials; Fluorine-18; Imaging; MRI; PET; Radiochemistry; SPECT